Damon L Meyer
Overview
Explore the profile of Damon L Meyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alley S, Benjamin D, Jeffrey S, Okeley N, Meyer D, Sanderson R, et al.
Bioconjug Chem
. 2008 Mar;
19(3):759-65.
PMID: 18314937
The linker component of antibody-drug conjugates (ADC) is a key feature in developing optimized therapeutic agents that are highly active at well tolerated doses. For maximal intratumoral drug delivery, linkers...
2.
Ryan M, Hering M, Peckham D, McDonagh C, Brown L, Kim K, et al.
Mol Cancer Ther
. 2007 Nov;
6(11):3009-18.
PMID: 18025285
B-cell maturation antigen (BCMA) is expressed on normal and malignant plasma cells and represents a potential target for therapeutic intervention. BCMA binds to two ligands that promote tumor cell survival,...
3.
Temming K, Meyer D, Zabinski R, Senter P, Poelstra K, Molema G, et al.
Mol Pharm
. 2007 Aug;
4(5):686-94.
PMID: 17683157
Cellular handling of drug delivery preparations en route to the lysosomal compartment has been extensively studied, but little is known about cellular handling of drugs subsequent to their release from...
4.
Jeffrey S, Nguyen M, Moser R, Meyer D, Miyamoto J, Senter P
Bioorg Med Chem Lett
. 2007 Feb;
17(8):2278-80.
PMID: 17293111
The minor groove binder beta-glucuronide drug-linker 3 was constructed from amino CBI 1 and determined to be a substrate for Escherichia coli beta-glucuronidase (EC 3.2.1.31), resulting in facile drug release....
5.
Temming K, Meyer D, Zabinski R, Dijkers E, Poelstra K, Molema G, et al.
Bioconjug Chem
. 2006 Nov;
17(6):1385-94.
PMID: 17105215
Induction of apoptosis in endothelial cells is considered an attractive strategy to therapeutically interfere with a solid tumor's blood supply. In the present paper, we constructed cytotoxic conjugates that specifically...
6.
Tse K, Jeffers M, Pollack V, McCabe D, Shadish M, Khramtsov N, et al.
Clin Cancer Res
. 2006 Feb;
12(4):1373-82.
PMID: 16489096
Purpose: Advanced melanoma is a highly drug-refractory neoplasm representing a significant unmet medical need. We sought to identify melanoma-associated cell surface molecules and to develop as well as preclinically test...
7.
Law C, Gordon K, Toki B, Yamane A, Hering M, Cerveny C, et al.
Cancer Res
. 2006 Feb;
66(4):2328-37.
PMID: 16489038
Metastatic renal cell carcinoma (RCC) is an aggressive disease refractory to most existing therapeutic modalities. Identifying new markers for disease progression and drug targets for RCC will benefit this unmet...
8.
Kung Sutherland M, Sanderson R, Gordon K, Andreyka J, Cerveny C, Yu C, et al.
J Biol Chem
. 2006 Feb;
281(15):10540-7.
PMID: 16484228
The chimeric anti-CD30 monoclonal antibody cAC10, linked to the antimitotic agents monomethyl auristatin E (MMAE) or F (MMAF), produces potent and highly CD30-selective anti-tumor activity in vitro and in vivo....
9.
Doronina S, Mendelsohn B, Bovee T, Cerveny C, Alley S, Meyer D, et al.
Bioconjug Chem
. 2006 Jan;
17(1):114-24.
PMID: 16417259
We have previously shown that antibody-drug conjugates (ADCs) consisting of cAC10 (anti-CD30) linked to the antimitotic agent monomethylauristatin E (MMAE) lead to potent in vitro and in vivo activities against...
10.
Jeffrey S, Nguyen M, Andreyka J, Meyer D, Doronina S, Senter P
Bioorg Med Chem Lett
. 2005 Nov;
16(2):358-62.
PMID: 16275070
Highly potent and novel derivatives of doxorubicin were linked to monoclonal antibodies (mAbs) for site-specific drug delivery. Drug linker 5 consisted of a dipeptide linker attached directly to the daunosamine...